No Data
No Data
Maxim Group Sticks to Their Buy Rating for Palisade Bio (PALI)
Express News | Palisade Bio Inc : Maxim Group Cuts Target Price to $2 From $8
Palisade Bio | 10-K: FY2024 Annual Report
$PALI Earnings Preview: Recent $PALI Insider Trading, Hedge Fund Activity, and More
12 Health Care Stocks Moving In Monday's Pre-Market Session
Palisade Bio Reports Encouraging Preliminary Safety and Tolerability Data for PALI-2108 in Phase 1a/b Study for Ulcerative Colitis